These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

821 related articles for article (PubMed ID: 28739313)

  • 1. Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment.
    Siddiqi OK; Ruberg FL
    Trends Cardiovasc Med; 2018 Jan; 28(1):10-21. PubMed ID: 28739313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature.
    Adam RD; Coriu D; Jercan A; Bădeliţă S; Popescu BA; Damy T; Jurcuţ R
    ESC Heart Fail; 2021 Aug; 8(4):2380-2396. PubMed ID: 34089308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sporadic Cardiac Amyloidosis by Amyloidogenic Transthyretin V122I Variant.
    Nehashi T; Oikawa M; Amami K; Kanno Y; Yokokawa T; Misaka T; Yamada S; Kunii H; Nakazato K; Ishida T; Takeishi Y
    Int Heart J; 2019 Nov; 60(6):1441-1443. PubMed ID: 31666456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amyloid cardiomyopathy.
    Kristen AV
    Herz; 2020 May; 45(3):267-271. PubMed ID: 32107564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy?
    Aus dem Siepen F; Hein S; Prestel S; Baumgärtner C; Schönland S; Hegenbart U; Röcken C; Katus HA; Kristen AV
    Clin Res Cardiol; 2019 Dec; 108(12):1324-1330. PubMed ID: 30953182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First Norwegian case of hereditary ATTR amyloidosis with a novel transthyretin variant.
    Lyng CS; Gude E; Hodt A; Knudsen EC
    Scand Cardiovasc J; 2023 Dec; 57(1):2174269. PubMed ID: 36734834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Late onset cardiomyopathy as presenting sign of ATTR A45G amyloidosis caused by a novel TTR mutation (p.A65G).
    Klaassen SHC; Lemmink HH; Bijzet J; Glaudemans AWJM; Bos R; Plattel W; van den Berg MP; Slart RHJA; Nienhuis HLA; van Veldhuisen DJ; Hazenberg BPC
    Cardiovasc Pathol; 2017; 29():19-22. PubMed ID: 28460244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Genetic Testing in Transthyretin (ATTR) Cardiac Amyloidosis.
    Gopal DM; Ruberg FL; Siddiqi OK
    Curr Heart Fail Rep; 2019 Oct; 16(5):180-188. PubMed ID: 31520266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
    Sekijima Y
    J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology, diagnosis, and management of cardiac amyloidosis.
    Bashir Z; Younus A; Dhillon S; Kasi A; Bukhari S
    J Investig Med; 2024 Oct; 72(7):620-632. PubMed ID: 38869161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Fibril-forming proteins: the amyloidosis. New hopes for a disease that cardiologists must know].
    Arbustini E; Gavazzi A; Merlini G
    Ital Heart J Suppl; 2002 Jun; 3(6):590-7. PubMed ID: 12116807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report.
    Yamamoto H; Hashimoto T; Kawamura S; Hiroe M; Yamashita T; Ando Y; Yokochi T
    J Med Case Rep; 2018 Dec; 12(1):370. PubMed ID: 30553273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac amyloidosis: updates in diagnosis and management.
    Mohty D; Damy T; Cosnay P; Echahidi N; Casset-Senon D; Virot P; Jaccard A
    Arch Cardiovasc Dis; 2013 Oct; 106(10):528-40. PubMed ID: 24070600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unfolding Cardiac Amyloidosis -From Pathophysiology to Cure.
    Ablasser K; Verheyen N; Glantschnig T; Agnetti G; Rainer PP
    Curr Med Chem; 2019; 26(16):2865-2878. PubMed ID: 29303069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver transplantation in transthyretin amyloidosis: issues and challenges.
    Carvalho A; Rocha A; Lobato L
    Liver Transpl; 2015 Mar; 21(3):282-92. PubMed ID: 25482846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amyloidosis as a Systemic Disease in Context.
    Cuddy SAM; Falk RH
    Can J Cardiol; 2020 Mar; 36(3):396-407. PubMed ID: 32145867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac Amyloidosis Treatment.
    Stern LK; Patel J
    Methodist Debakey Cardiovasc J; 2022; 18(2):59-72. PubMed ID: 35414852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal Involvement in Transthyretin Amyloidosis: The Double Presentation of Transthyretin Amyloidosis Deposition Disease.
    Fenoglio R; Baldovino S; Barreca A; Bottasso E; Sciascia S; Sbaiz L; Papotti M; Roccatello D
    Nephron; 2022; 146(5):481-488. PubMed ID: 35307708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Transthyretin-related amyloidotic cardiomyopathy: looking for the etiological treatment].
    Longhi S; Gagliardi C; Milandri A; Manuzzi L; Rapezzi C
    G Ital Cardiol (Rome); 2014 May; 15(5):293-300. PubMed ID: 25002169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic testing improves identification of transthyretin amyloid (ATTR) subtype in cardiac amyloidosis.
    Brown EE; Lee YZJ; Halushka MK; Steenbergen C; Johnson NM; Almansa J; Tedford RJ; Cingolani O; Russell SD; Sharma K; Judge DP
    Amyloid; 2017 Jun; 24(2):92-95. PubMed ID: 28494620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.